Skip to Content

Posts tagged with "Alzheimer’s Disease"

  • Alzheimer's Disease

    TauRx’s Funding Is Odd

    I still get inquiries about TauRx and their work on Alzheimer’s. There’s an awful lot of pent-up demand in that field, and it’s getting worse every year. The latest is that the company has ten million more dollars in a follow-on investment option from the Dundee Corporation of Toronto. Who they? That’s what I wondered… Read More
  • Alzheimer's Disease

    CETP, Alzheimer’s, Monty Hall, and Roulette. And Goats.

    CETP, now there’s a drug target that has incinerated a lot of money over the years. Here’s a roundup of compounds I posted on back last summer, with links to their brutal development histories. I wondered here about what’s going to happen with this class of compounds: will one ever make it as a drug?… Read More
  • Alzheimer's Disease

    Eli Lilly’s Brave Alzheimer’s Talk

    I’m a bit baffled by Eli Lilly’s strategy on Alzheimer’s. Not the scientific side of it – they’re going strongly after the amyloid hypothesis, with secretase inhibitors and antibody therapies, and if I were committed to the amyloid hypothesis, that’s probably what I’d be doing, too. It is, after all, the st… Read More
  • Alzheimer's Disease

    Merck Presses Ahead on Alzheimer’s:

    One Alzheimer’s compound recently died off in the clinic – Bristol-Myers Squibb’s avagacestat, a gamma-secretase inhibitor, has been pulled from trials. The compound “did not establish a profile that supported advancement” to Phase III, says the company. Gamma-secretase has been a troubled area for some time, highlight… Read More
  • Alzheimer's Disease

    TauRx Goes Into Phase III For Alzheimer’s

    I can’t even count the number of e-mails I’ve gotten over the last few years asking about TauRx and their Alzheimer’s program, which made a big splash back in 2008. Finally, there’s some news to report. The company is starting Phase III clinical trials, and has announced new financing to see these through. The company… Read More
  • Alzheimer's Disease

    And Since We’re Talking About Insider Trading

    Here’s something from just this morning, a whopping large case on illegal trading in Wyeth and Elan stock. This one involves a hedge fund manager, Mathew Martoma, and (quite disturbingly), Dr. Sidney Gilman of the University of Michigan, who was the lead investigator on a very large bapineuzumab trial for Alzheimer’s. His conduct appear… Read More
  • Alzheimer's Disease

    JNK3 – Something New for Alzheimer’s?

    There’s been an interesting recent development in the biology of Alzheimer’s disease. c-Jun N-terminal kinase 3 (JNK3, known to those in the field, semi-affectionately, as “Junk-Three”) is expressed mostly in the CNS, and has been implicated as a player in Parkinson’s and neurodegeneration in general. There’s bee… Read More
  • Alzheimer's Disease

    The Coming Battle Over Alzheimer’s Disease

    Solanezumab is a story that won’t go away. Eli Lilly’s antibody therapy for Alzheimer’s is the subject of a lot of arguing among investors: some people (and I’m one of them) think that there is no strong evidence for its efficacy, not yet, and that the amount of time and effort devoted to finding that… Read More
  • Alzheimer's Disease

    Another Prospective Alzheimer’s Trial

    I wrote here about a prospective Alzheimer’s trial that’s starting soon among a population in Colombia, and now comes word of another large effort along the same lines. DIAN, the Dominantly Inherited Alzheimer’s Network, will test several current Alzheimer’s candidates in groups of people around the world with genetic mutati… Read More
  • Alzheimer's Disease

    Lilly’s Solanezumab: Did It Actually Work?

    “Hope Rises For Alzheimer’s Treatment, Scientists Say”. Not this scientist. That’s a composite of headlines, but it captures the unfortunate tone. We’re talking about solanezumab, Eli Lilly’s antibody therapy. The company presented analysis of their trial data yesterday, and put a very optimistic face on things.… Read More
...789...